NeoGenomics, Inc. (NEO) Stock Price & Analysis
NeoGenomics, Inc. (NEO) closed at USD 17.25 on Thursday, October 15, 2026, up 2.19% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 16.88; the Oct 15, 2026 session ranged USD 16.61–17.34 on volume of 1,315,084 shares. Market capitalization is $2.22B, with a 52-week range of USD 7.07–20.15 (NCM). Source: Nexqual, retrieved October 16, 2026 at 05:21 UTC.
Also available as compact Markdown for AI agents: nexqual.com/NEO.md
Key facts (NEO)
- Last four reported quarters (through Jun 30, 2026): revenue $766M, net income -$51.9M (-6.8% margin), free cash flow -$7.4M (SEC filings).
- Insider open-market sales, last ~7 months: 3 Form 4 filings, $440K; 1 not under a Rule 10b5-1 plan ($321K).
- Analysts: Buy (mean 2.08 on a 1–5 scale) (12 analysts), mean target USD 21.85 (range 16.5–35).
- Total return with dividends: 1Y +67.8% vs S&P 500 +18.1%; 5Y -60.2% vs S&P 500 +85.1%.
- Next earnings: 2026-10-28, EPS estimate USD 0.06, revenue estimate $207M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (NEO)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $484M | $510M | $592M | $661M | $727M | $766M |
| Gross profit | $187M | $188M | $245M | $290M | $314M | — |
| Operating income | -$119M | -$158M | -$108M | -$92.1M | -$116M | -$68.4M |
| Net income | -$8.3M | -$144M | -$88.0M | -$78.7M | -$108M | -$51.9M |
| Free cash flow | -$90.9M | -$96.9M | -$30.7M | -$34.0M | -$21.8M | -$7.4M |
| Gross margin | 38.6% | 36.9% | 41.3% | 43.9% | 43.2% | — |
| Operating margin | -24.5% | -30.9% | -18.2% | -13.9% | -15.9% | -8.9% |
| Net margin | -1.7% | -28.3% | -14.9% | -11.9% | -14.9% | -6.8% |
| Revenue growth | +9.0% | +5.2% | +16.1% | +11.6% | +10.1% | — |
| Cash + short-term investments | $515M | — | — | $367M | $160M | — |
| Total debt | $533M | $535M | $538M | $541M | $342M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (NEO)
P/S 2.9x · EV/Sales 3.2x · P/B 2.8x · FCF yield -0.33% · Earnings yield -2.34% · Net debt $229M · EV $2.44B
Insider sales (SEC Form 4, open-market, last ~7 months) (NEO)
2 of 3 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan |
|---|---|---|---|---|---|---|
| 2026-08-04 | Aunan Greg D | Chief Accounting Officer | 20,000 | $321K | 79.5% | No |
| 2026-06-15 | Tetrault Lynn A. | Director | 5,307 | $59K | 5.4% | Yes |
| 2026-06-09 | Tetrault Lynn A. | Director | 5,307 | $60K | 5.1% | Yes |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Analysts (NEO)
Consensus Buy (mean 2.08 on a 1–5 scale), 12 analysts; mean target USD 21.85 (low 16.5, high 35).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-06 | StoneX | Target raised | Buy | $16 → $20 |
| 2026-10-06 | Needham | Target raised | Buy | $19 → $22 |
| 2026-10-06 | BTIG | Upgrade | Neutral → Buy | $28 |
| 2026-07-29 | Needham | Target raised | Buy | $15 → $19 |
| 2026-07-24 | Benchmark | Target raised | Buy | $11 → $16 |
Total return (dividends reinvested) (NEO)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | +67.8% | -60.2% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | +68.1% | -16.8% |
| Volatility (annualized) | 53.5% | 67.5% |
| Max drawdown | -45.6% (Jan 2026→Mar 2026) | -88.8% (Oct 2021→Jul 2025) |
Key Statistics (as of October 16, 2026 at 05:21 UTC)
| Price | USD 17.25 |
|---|---|
| Change | ▲ 2.19% (up) |
| Previous Close | USD 16.88 |
| Open | USD 16.88 |
| Day Range | USD 16.61 – 17.34 |
| 52-Week Range | USD 7.07 – 20.15 |
| Volume | 1,315,084 shares |
| Market Cap | $2.22B |
| Exchange | NCM |
Technical Analysis (NEO)
Nexqual's technical model rates NEO "SELL" based on 1 bullish and 4 bearish signals across 127 daily candles, as of October 16, 2026 at 05:21 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 46.85 (neutral) |
| vs SMA50 | Below (USD 17.53) |
| MACD | -0.33 (negative) |
Analyst Ratings (NEO)
Wall Street analysts rate NEO "Buy" based on 12 analysts, with a mean price target of USD 21.85 (range USD 16.5–35), per Nexqual as of October 16, 2026 at 05:21 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 12 |
| Mean Target | USD 21.85 |
| High Target | USD 35 |
| Low Target | USD 16.5 |
| Buy / Hold / Sell | 9 / 3 / 0 |
Earnings (NEO)
| Next Earnings Date | 2026-10-28 |
|---|---|
| EPS Estimate | USD 0.06 |
| Revenue Estimate | $207.33M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.05 vs est 0.03 ▲ beat |
| 2026-03-31 | USD 0.01 vs est 0 ▲ beat |
| 2025-12-31 | USD 0.06 vs est 0.04 ▲ beat |
| 2025-09-30 | USD 0.03 vs est 0.02 ▲ beat |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Financials & Fundamentals (NEO)
| Total Revenue | $766.29M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +11.20% |
| Gross Margin | +43.92% |
| Operating Margin | -4.84% |
| Profit Margin | -6.77% |
| ROE | -6.33% |
| Debt / Equity | 0.57 |
| Current Ratio | 3.6 |
| Total Cash | $145.54M |
| Total Debt | $448.37M |
| Free Cash Flow (fiscal year ended Dec 2025, SEC 10-K) | -$21.78M (-3.0% of revenue) |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Financial Health Score (NEO)
Nexqual rates NeoGenomics, Inc.'s overall financial health "Mixed" across five dimensions, as of October 16, 2026 at 05:21 UTC.
| Growth | Solid — Revenue +10% YoY (annual) |
|---|---|
| Profitability | Mixed — Gross margin 44%, operating -5% |
| Balance Sheet | Strong — $146M cash vs $448M debt |
| Cash Flow | Weak — FCF negative: -$22M (FY ended Dec 2025, 10-K), burning cash |
| Efficiency | Critical — ROE -6%, ROA -1.9% |
Ownership (NEO)
| Insider Ownership | +2.11% |
|---|---|
| Institutional Ownership | +115.19% |
| Shares Outstanding | 128.48M |
| Float | 117.01M |
| Short % of Float | +13.00% |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Leadership (NEO)
NeoGenomics, Inc. is led by Anthony P. Zook (age 64), CEO & Director, per Nexqual as of October 16, 2026 at 05:21 UTC.
| CEO & Director | Anthony P. Zook (age 64) |
|---|---|
| President & COO | Warren Stone (age 52) |
| Executive VP & CFO | Abhishek Jain (age 49) |
| Vice President of Investor Relations | Andrew Frederick Brackmann C.F.A. |
| Vice President of Compliance & Privacy | Clarence Cooper |
Major Backers & Investors (NEO)
Notable institutional backers of NeoGenomics, Inc. include First Light Asset Management, LLC, First Trust Advisors LP, Greenhouse Funds, LLLP, according to Nexqual as of October 16, 2026 at 05:21 UTC.
Active Investors
| Investor | Stake |
|---|---|
| First Light Asset Management, LLC | 9.56% |
| First Trust Advisors LP | 7.87% |
| Greenhouse Funds, LLLP | 6.67% |
| First TRT Exch-Trd Fd.-First TRT NYSE Arca Biotechnology Index Fd. | 4.99% |
| Nomura Asset Management International Inc | 3.92% |
| Braidwell LP | 3.83% |
| Schroder Investment Management Group | 3.38% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 25.03% |
| Vanguard Group | 18.79% |
| State Street | 4.17% |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| WGS | GeneDx Holdings Corp. | USD 70.22 | ▲ 8.1% |
| PSNL | Personalis, Inc. | USD 15.93 | ▲ 0.5% |
| CDNA | CareDx, Inc. | USD 66.68 | ▲ 1.9% |
| VCYT | Veracyte, Inc. | USD 44.39 | ▲ 2.97% |
| FRNM | Freenome, Inc. | USD 12.29 | ▼ 2.81% |
| ADPT | Adaptive Biotechnologies Corpor | USD 25.58 | ▲ 1.19% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:21 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt